AstraZeneca immunotherapy wins first approval in bladder cancer – Reuters
Reuters |
AstraZeneca immunotherapy wins first approval in bladder cancer
Reuters U.S. regulators have approved AstraZeneca's key immunotherapy drug durvalumab as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars. The approval, while … AstraZeneca gains FDA approval for durvalumab |
